Aibotics, Inc. (OTC: AIBT) is a pre-revenue biotechnology company focused on psilocybin-based mental health therapeutics. The company has no product revenue; its financing has consisted of convertible notes and common stock issuances, with net cash from financing activities of $529,083 for the year ended December 31, 2025. Aibotics holds a supply agreement with Havn Life Sciences (CSE: HAVN) for naturally derived psilocybin as an Active Pharmaceutical Ingredient, intended for use by universities, researchers, and pharmaceutical companies developing psilocybin-based treatments. The company also pursues integration with parent-affiliated Ehave, Inc. (OTC: EHVVF) EEG brain-cap technology to capture neurological data during psilocybin therapy. General and administrative expenses were $1,846,856 for the year ended December 31, 2025, consisting primarily of consulting fees, legal and professional services, and board compensation. The company carried a net loss of $1,848,275 for the year ended December 31, 2024 and reported a going-concern qualification in its consolidated financial statements as of December 31, 2025.

Revenue model

No product revenue reported for the years ended December 31, 2025 or 2024. Operations are funded through convertible note issuances and common stock sales. The company is pre-commercial.

Products and services

Psilocybin Active Pharmaceutical Ingredient (API) sourced from Havn Life Sciences under a supply agreement, intended for testing by universities, researchers, and pharmaceutical companies. EEG brain-cap technology integration under negotiation with Ehave, Inc. for neurological data capture during mental health therapies.

Customers and end markets

Target customers are universities, researchers, and pharmaceutical companies seeking to develop psilocybin-based treatments and therapies. End market is psilocybin-assisted mental health treatment, with focus on depression and addiction applications.

Value-chain role

Development-stage company positioned as a psilocybin API supplier and data-therapeutics integrator. Sources psilocybin API from Havn Life Sciences and seeks to integrate EEG measurement technology from parent-affiliated Ehave, Inc.

Geographic exposure

Incorporated in the United States. Psilocybin supply partner Havn Life Sciences is a Canadian corporation. No geographic revenue breakdown disclosed in the filing.

Source: SEC 10-K, filed 2026-04-15

Industry: Medicinal Chemicals & Botanical Products Peers: Assure Holdings Corp. Cardiff Lexington Corp CVS Health Corp Hypha Labs Inc